Pharmalot Ed Silverman STAT Plus: Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible
Pharmalot Ed Silverman STAT Plus: AbbVie settles litigation with another drug maker over a biosimilar version of Humira
First Opinion Dana P. Goldman and Tomas J. Philipson Biosimilars competition helps patients more than generic competition
Health Michelle Andrews — Kaiser Health News Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch
First Opinion Gillian Woollett The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means
Pharmalot Ed Silverman STAT Plus: FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug
Opinions+ Pierre Bourdage STAT Plus: Three steps toward creating a functioning U.S. biosimilars market
Pharmalot Ed Silverman STAT Plus: U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition
Pharmalot Ed Silverman STAT Plus: FDA approves an interchangeable biosimilar version of Humira, but health care savings are dubious
Pharma Ed Silverman STAT Plus: AbbVie loses a lawsuit over Humira trade secrets it claimed were stolen
First Opinion Howard S. Hochster FDA’s naming rule for biosimilars has undermined Congress and health care
Pharmalot Ed Silverman STAT Plus: FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?
Pharmalot Ed Silverman STAT Plus: AbbVie accuses a company of recruiting an employee in order to steal Humira secrets
Pharmalot Ed Silverman STAT Plus: Once again, the viability of the U.S. biosimilar market is thrown into question
Pharmalot Ed Silverman STAT Plus: In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition
Pharmalot Ed Silverman STAT Plus: What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years
Pharmalot Ed Silverman STAT Plus: Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs
Pharmalot Ed Silverman STAT Plus: Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks
Pharmalot Ed Silverman STAT Plus: Biosimilars got the cold shoulder from health plans when it came to preferred coverage
Pharmalot Ed Silverman STAT Plus: Large employers could have saved money if more biosimilars had been prescribed
Pharmalot Ed Silverman STAT Plus: Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins
Business Matthew Herper Merck to spin off new $6.5 billion firm focused on women’s health, older drugs
Pharmalot Ed Silverman STAT Plus: FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake
Politics Lev Facher STAT Plus: Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation
Pharmalot Ed Silverman STAT Plus: Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals